Factors Associated with Medication Beliefs in Patients with Parkinson’s Disease: A Cross-Sectional Study

Sung-Reul KIM; Ji-Young KIM; Hye-Young KIM; Hui-Young SO; Sun-Ju CHUNG.
Journal of Movement Disorders ; : 133-143, 2021.
Artículo en Inglés | WPRIM | ID: wpr-900354

Documentos relacionados

  1. Factors Associated with Medication Beliefs in Patients with Parkinson’s Disease: A Cross-Sectional Study
  2. Amantadine use in the French prospective NS-Park cohort.
  3. Factors Associated with Medication Beliefs in Patients with Parkinson's Disease: A Cross-Sectional Study.
  4. Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations.
  5. Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.
  6. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
  7. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
  8. Implications of dopaminergic medication withdrawal in Parkinson's disease.
  9. Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.
  10. Limiting Monoamines Degradation Increases L-DOPA Pro-Locomotor Action in Newborn Rats.